W. Blackaby

发表

Optimization of Potent and Selective Ataxia Telangiectasia-Mutated Inhibitors Suitable for a Proof-of-Concept Study in Huntington's Disease Models.

S. Dowler, M. Lamers, R. Cachope, 2019, Journal of medicinal chemistry.

Discovery of a novel class of inhaled dual pharmacology muscarinic antagonist and β2 agonist (MABA) for the treatment of chronic obstructive pulmonary disease (COPD).

B. Riccardi, A. Rizzi, N. Cesari, 2021, Bioorganic & medicinal chemistry letters.

Optimization of Pan-Pim Kinase Activity and Oral Bioavailability Leading to Diaminopyrazole (GDC-0339) for the Treatment of Multiple Myeloma.

A. Ebens, C. Noland, J. Lyssikatos, 2019, Journal of medicinal chemistry.

Discovery of Clinical Candidate CHF-6366: A Novel Super-soft Dual Pharmacology Muscarinic Antagonist and β2 Agonist (MABA) for the Inhaled Treatment of Respiratory Diseases.

S. Catinella, L. Venturi, P. Puccini, 2022, Journal of medicinal chemistry.

Targeting the m6A RNA modification pathway blocks SARS-CoV-2 and HCoV-OC43 replication

I. Mohr, T. Kouzarides, D. Depledge, 2021, Genes & development.

Developing HDAC4-Selective Protein Degraders To Investigate the Role of HDAC4 in Huntington’s Disease Pathology

T. Vogt, G. Mcallister, C. Dominguez, 2022, Journal of medicinal chemistry.

Imidazo[1,2-a]pyrimidines as functionally selective GABA(A) ligands.

A. Pike, J. Atack, K. Wafford, 2006, Bioorganic & medicinal chemistry letters.

Imidazo[1,2-a]pyrimidines as Functionally Selective and Orally Bioavailable GABAAα2/α3 Binding Site Agonists for the Treatment of Anxiety Disorders

Joanna Stanley, A. Pike, J. Atack, 2006 .

Synthesis of pyrido[2,3-d]pyridazines and pyrazino[2,3-d]-pyridazines—novel classes of GABAA receptor benzodiazepine binding site ligands

R. Lewis, R. Carling, S. Bourrain, 2006 .

Pyrazolopyridinones as functionally selective GABAA ligands.

R. Mckernan, J. Atack, K. Wafford, 2005, Bioorganic & medicinal chemistry letters.

Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia

Andrew J. Bannister, Dan Leggate, M. Eleftheriou, 2021, Nature.

Pharmacological Inhibition of the RNA m6a Writer METTL3 As a Novel Therapeutic Strategy for Acute Myeloid Leukemia

Dan Leggate, T. Kouzarides, G. Vassiliou, 2019, Blood.

A Pyridazine Series of α2/α3 Subtype Selective GABAA Agonists for the Treatment of Anxiety

S. Tye, A. Pike, J. Atack, 2006 .

Evaluation of 5-(Trifluoromethyl)-1,2,4-oxadiazole-Based Class IIa HDAC Inhibitors for Huntington's Disease.

G. Mcallister, C. Dominguez, V. Beaumont, 2021, ACS medicinal chemistry letters.

The in vivo properties of pagoclone in rat are most likely mediated by 5′-hydroxy pagoclone

G. Dawson, R. Mckernan, J. Atack, 2006, Neuropharmacology.

Probing Mechanisms of CYP3A Time-Dependent Inhibition Using a Truncated Model System.

J. Lyssikatos, Suzanne Tay, P. Fan, 2015, ACS medicinal chemistry letters.

A pyridazine series of alpha2/alpha3 subtype selective GABA A agonists for the treatment of anxiety.

S. Tye, A. Pike, J. Atack, 2006, Journal of Medicinal Chemistry.

Evaluation of 5 ‑ (Tri ﬂ uoromethyl)-1,2,4-oxadiazole-Based Class IIa HDAC Inhibitors for Huntington ’ s Disease

G. Mcallister, C. Dominguez, V. Beaumont, 2021 .

Identification of an Orally Bioavailable, Potent, and Selective Inhibitor of GlyT1.

A. Pike, H. Burns, T. Hamill, 2010, ACS medicinal chemistry letters.

Optimization of M3 Antagonist-PDE4 Inhibitor (MAPI) Dual Pharmacology Molecules for the Treatment of COPD.

F. Amadei, P. Puccini, G. Villetti, 2023, Journal of medicinal chemistry.

Discovery of M3 Antagonist-PDE4 Inhibitor Dual Pharmacology Molecules for the Treatment of Chronic Obstructive Pulmonary Disease.

F. Amadei, P. Puccini, G. Villetti, 2021, Journal of medicinal chemistry.

Structure-Based Exploration of Selectivity for ATM Inhibitors in Huntington's Disease.

M. Lamers, R. Cachope, G. Mcallister, 2021, Journal of medicinal chemistry.

Inhibition of METTL3 results in a cell-intrinsic interferon response that enhances anti-tumour immunity.

M. Dawson, M. Albertella, G. Tsagkogeorga, 2023, Cancer discovery.

Probing Mechanisms of CYP3A Time-Dependent Inhibition Using a Truncated Model System.

J. Lyssikatos, Suzanne Tay, P. Fan, 2015, ACS medicinal chemistry letters.